195 related articles for article (PubMed ID: 28709429)
1. Efficacy of rituximab in non-paraneoplastic autoimmune retinopathy.
Boudreault K; Justus S; Sengillo JD; Schuerch K; Lee W; Cabral T; Tsang SH
Orphanet J Rare Dis; 2017 Jul; 12(1):129. PubMed ID: 28709429
[TBL] [Abstract][Full Text] [Related]
2. Combination Treatment with Rituximab and Bortezomib in a Patient with Non-Paraneoplastic Autoimmune Retinopathy.
Benson MD; Plemel DJA; Yacyshyn E; Sandhu I; MacDonald IM; Baker CF
Ocul Immunol Inflamm; 2020 Aug; 28(6):958-965. PubMed ID: 31418623
[TBL] [Abstract][Full Text] [Related]
3. Outcomes in Autoimmune Retinopathy Patients Treated With Rituximab.
Davoudi S; Ebrahimiadib N; Yasa C; Sevgi DD; Roohipoor R; Papavasilieou E; Comander J; Sobrin L
Am J Ophthalmol; 2017 Aug; 180():124-132. PubMed ID: 28483493
[TBL] [Abstract][Full Text] [Related]
4. Rituximab treatment for nonparaneoplastic autoimmune retinopathy.
Fox A; Jeffrey B; Hasni S; Nussenblatt R; Sen HN
Can J Ophthalmol; 2015 Dec; 50(6):e101-4. PubMed ID: 26651312
[No Abstract] [Full Text] [Related]
5. Management of autoimmune retinopathies with immunosuppression.
Ferreyra HA; Jayasundera T; Khan NW; He S; Lu Y; Heckenlively JR
Arch Ophthalmol; 2009 Apr; 127(4):390-7. PubMed ID: 19365013
[TBL] [Abstract][Full Text] [Related]
6. Non-paraneoplastic autoimmune retinopathy that developed in fellow eye 10 years after onset in first eye: a case report.
Miura G; Baba T; Iwase T; Ohde H; Kanda A; Saito W; Ishida S; Yamamoto S
BMC Ophthalmol; 2020 Apr; 20(1):132. PubMed ID: 32252709
[TBL] [Abstract][Full Text] [Related]
7. The role of cystoid macular edema as a marker in the progression of non-paraneoplastic autoimmune retinopathy.
Finn AP; Thomas AS; Stinnett SS; Keenan RT; Grewal DS; Jaffe GJ
Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):1867-1873. PubMed ID: 30128606
[TBL] [Abstract][Full Text] [Related]
8. Electroretinographic improvement after rituximab therapy in a patient with autoimmune retinopathy.
Uludag G; Onal S; Arf S; Sayman Muslubas I; Selcukbiricik F; Koc Akbay A; Molinas Mandel N
Am J Ophthalmol Case Rep; 2016 Jul; 2():4-7. PubMed ID: 29503888
[TBL] [Abstract][Full Text] [Related]
9. Rituximab treatment for autoimmune limbic encephalitis in an institutional cohort.
Lee WJ; Lee ST; Byun JI; Sunwoo JS; Kim TJ; Lim JA; Moon J; Lee HS; Shin YW; Lee KJ; Kim S; Jung KH; Jung KY; Chu K; Lee SK
Neurology; 2016 May; 86(18):1683-91. PubMed ID: 27037228
[TBL] [Abstract][Full Text] [Related]
10. Unilateral cancer-associated retinopathy: diagnosis, serology and treatment.
Roels D; Ueno S; Talianu CD; Draganova D; Kondo M; Leroy BP
Doc Ophthalmol; 2017 Dec; 135(3):233-240. PubMed ID: 28815346
[TBL] [Abstract][Full Text] [Related]
11. Non-Paraneoplastic Autoimmune Retinopathy: The First Case Report in Korea.
Choi EY; Kim M; Adamus G; Koh HJ; Lee SC
Yonsei Med J; 2016 Mar; 57(2):527-31. PubMed ID: 26847311
[TBL] [Abstract][Full Text] [Related]
12. Autoantibodies against retinal proteins in paraneoplastic and autoimmune retinopathy.
Adamus G; Ren G; Weleber RG
BMC Ophthalmol; 2004 Jun; 4():5. PubMed ID: 15180904
[TBL] [Abstract][Full Text] [Related]
13. Non-paraneoplastic related retinopathy: clinical challenges and review.
Takiuti JT; Takahashi VKL; Xu CL; Jauregui R; Tsang SH
Ophthalmic Genet; 2019 Aug; 40(4):293-297. PubMed ID: 31394964
[TBL] [Abstract][Full Text] [Related]
14. Antireconverin antibodies in ocular chronic graft versus host disease: A new cause of nonparaneoplasic autoimmune retinopathy.
Aguilar González M; Marín Payá E; García Gil R; Feliciano Sánchez A; Gómez-Lechón Quirós L; España Gregori E
Eur J Ophthalmol; 2023 Jul; 33(4):NP105-NP110. PubMed ID: 36052416
[TBL] [Abstract][Full Text] [Related]
15. Off-label use of rituximab in autoimmune disease in the Top End of the Northern Territory, 2008-2016.
Wongseelashote S; Tayal V; Bourke PF
Intern Med J; 2018 Feb; 48(2):165-172. PubMed ID: 28742259
[TBL] [Abstract][Full Text] [Related]
16. Off-label use of rituximab in 196 patients with severe, refractory systemic autoimmune diseases.
Ramos-Casals M; García-Hernández FJ; de Ramón E; Callejas JL; Martínez-Berriotxoa A; Pallarés L; Caminal-Montero L; Selva-O'Callaghan A; Oristrell J; Hidalgo C; Pérez-Alvarez R; Micó ML; Medrano F; Gómez de la Torre R; Díaz-Lagares C; Camps M; Ortego N; Sánchez-Román J;
Clin Exp Rheumatol; 2010; 28(4):468-76. PubMed ID: 20525449
[TBL] [Abstract][Full Text] [Related]
17. Successful Combination Therapy with Rituximab and Glucocorticoids for Autoimmune Optic Neuropathy.
Sasaki S; Asahara D; Kaneko K; Komatsumoto S
Am J Case Rep; 2015 Jun; 16():357-60. PubMed ID: 26057570
[TBL] [Abstract][Full Text] [Related]
18. Rituximab Monotherapy versus Rituximab and Bortezomib Combination Therapy for Treatment of Non-paraneoplastic Autoimmune Retinopathy.
Maleki A; Colombo A; Look-Why S; Peter Y Chang BA; Anesi SD; Anesi SD
J Ophthalmic Vis Res; 2022; 17(4):515-528. PubMed ID: 36620716
[TBL] [Abstract][Full Text] [Related]
19. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases.
El-Hallak M; Binstadt BA; Leichtner AM; Bennett CM; Neufeld EJ; Fuhlbrigge RC; Zurakowski D; Sundel RP
J Pediatr; 2007 Apr; 150(4):376-82. PubMed ID: 17382113
[TBL] [Abstract][Full Text] [Related]
20. Clinical and electrophysiologic characterization of paraneoplastic and autoimmune retinopathies associated with antienolase antibodies.
Weleber RG; Watzke RC; Shults WT; Trzupek KM; Heckenlively JR; Egan RA; Adamus G
Am J Ophthalmol; 2005 May; 139(5):780-94. PubMed ID: 15860281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
